Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy.
Patients receiving maintenance hemodialysis (HD) present with hemostatic abnormalities, which may be aggravated by comorbid conditions, especially liver disease. The factors that influence plasma levels of thrombomodulin (TM), an initiator of the anticoagulant protein C pathway, and those of tissue factor (TF), which triggers the extrinsic coagulation pathway, were assessed. In 63 HD patients, TM and TF levels were higher than those in healthy controls. In bivariate analysis, TF positively correlated with TM, and both were directly associated with the presence of viral hepatitis B or C marker, serum liver enzymes, use of erythropoietin therapy, hemoglobin levels, and duration of HD therapy, and inversely correlated with body mass index. TF was also positively associated with plasma von Willebrand factor (vWF) antigen, and inversely associated with activated partial thromboplastin time. In multivariate analysis, increased vWF, alanine aminotransferase, and use of erythropoietin independently predicted both TF and TM levels. HD patients with vWF and ALT levels lower than middle, and not treated with erythropoietin had normal TF but increased TM concentrations compared with levels in healthy controls. Increased plasma levels of TM and TF in patients on maintenance HD are surrogates of vascular endothelial injury. Liver disease and use of erythropoietin treatment are also important determinants of these markers, and should be considered in further studies.
Borawski
Jacek
J
Department of Nephrology and Internal Medicine, Medical Academy, Bialystok, Poland. jborawski@post.pl
Naumnik
Beata
B
Mysliwiec
Michal
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D004796:Clinical Enzyme Tests; D003430:Cross-Sectional Studies; D004730:Endothelium, Vascular / Q000473:pathology*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006525:Hepatitis, Viral, Human / Q000097:blood; D006801:Humans; D008107:Liver Diseases / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D006435:Renal Dialysis / Q000009:adverse effects*; D018180:Thrombomodulin / Q000097:blood*; D013925:Thromboplastin / Q000032:analysis*; D014841:von Willebrand Factor / Q000032:analysis
D015415:Biomarkers; D018180:Thrombomodulin; D014841:von Willebrand Factor; D004921:Erythropoietin; D013925:Thromboplastin